Immunic (IMUX) Income towards Parent Company (2013 - 2026)

Immunic has reported Income towards Parent Company for 14 years, with the latest figure at -$35.8 million in Q1 2026.

• Quarterly Income towards Parent Company fell 34.31% year-over-year to -$35.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$232.4 million (down 129.02% YoY) and the FY2025 annual result came in at -$222.1 million, down 4.87% from the prior year.
• Income towards Parent Company climbed to -$35.8 million in Q1 2026 per IMUX's latest filing, from -$143.0 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$19.9 million in Q3 2022 and troughed at -$143.0 million in Q4 2025.
• A 5-year average of -$44.0 million and a median of -$26.6 million in 2023 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2024: Income towards Parent Company slumped 497.2% in 2022, then jumped 79.29% in 2024.
• Over 5 years, Income towards Parent Company stood at -$129.7 million in 2022, then advanced by 6.01% to -$121.9 million in 2023, then surged by 79.29% to -$25.2 million in 2024, then slumped by 466.57% to -$143.0 million in 2025, then soared by 74.96% to -$35.8 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$35.8 million, -$143.0 million, and -$26.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.